Amyris Moving 30 Molecules Through R&D Pipeline, Streamlining Consumer Portfolio
Executive Summary
Amyris, Inc. is developing 30 molecules using its bio-fermentation technology, negotiating a bio-manufacturing joint venture that could yield $50m-$100m in proceeds, and simplifying its Consumer portfolio to unlock value. Cost containment and liquidity will continue to be key priorities for the synthetic biotech firm while it targets up to 100% revenue growth in fiscal 2023.
You may also be interested in...
In Bankruptcy, Amyris To Sell Consumer Brands, Turn Focus To Smaller Ingredients Business
Synthetic biotech company Amyris files for Chapter 11 bankruptcy for its multiple US corporate entities and plans to sell its consumer brands.
Lauder's Skin Aging Research, Amyris CEO Change, BrainTrust Fund For Black Entrepreneurs; Beauty News
The Estee Lauder Companies will spotlight its latest skin health and aging research at the 25th World Congress of Dermatology in Singapore 3-8 July. More beauty news from Mary Kay, L’Oreal/Kerastase, Amyris, Half Magic Beauty, and BrainTrust Founders Studio.
Givaudan Strikes Deal For Amyris Ingredients, Long-Term Partnership
The deal has Amyris selling three key cosmetic ingredients to Givaudan and producing more biotech ingredients for the Swiss firm over the long term. “In the future, we will continue to push the boundaries of biotech, creating new sustainable innovations for a better beauty future,” says Givaudan’s Maurizio Volpi, president, Fragrance and Beauty.